CureVac N.V. (CVAC)
NASDAQ: CVAC
· Real-Time Price · USD
5.45
0.06 (1.11%)
At close: Oct 03, 2025, 3:59 PM
5.45
0.00%
After-hours: Oct 03, 2025, 06:57 PM EDT
1.11% (1D)
| Bid | 5.41 |
| Market Cap | 1.23B |
| Revenue (ttm) | 510.51M |
| Net Income (ttm) | 193.64M |
| EPS (ttm) | 1.01 |
| PE Ratio (ttm) | 5.4 |
| Forward PE | -9.62 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 5.46 |
| Volume | 528,957 |
| Avg. Volume (20D) | 628,352 |
| Open | 5.41 |
| Previous Close | 5.39 |
| Day's Range | 5.40 - 5.45 |
| 52-Week Range | 2.37 - 5.72 |
| Beta | 2.51 |
| Ex-Dividend Date | n/a |
About CVAC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CVAC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CVAC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsCureVac N.V. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+37.59%
CureVac shares are trading higher after BioNTech a...
Unlock content with
Pro Subscription
4 months ago
+10.59%
CureVac shares are trading higher following Q1 reported financial results.
1 month ago · proactiveinvestors.co.uk
GSK secures $370 million settlement and future royalties in CureVac mRNA patent disputeGSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine tec...
